nach oben

Reactions Weekly

Erschienen in:

01.08.2019 | Case report

Bevacizumab

Hypersensitivity reaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In an observational, prospective, single-centre study involving 73 patients (1 October 2014 to 1 April 2016), a patient [age and sex not stated] was described, who developed hypersensitivity reaction (HSR) while receiving antineoplastic therapy with bevacizumab. The patient, started receiving bevacizumab infusion 10 mg/kg administered in over 20 minutes [type of cancer not specified]. However, the patient developed a mild grade I HSR, which the patient described as a burning sensation in the throat. The HSR was transient and no medications were required. …

Garcia Gil S, et al. Ten-minute administration of bevacizumab. European Journal of Hospital Pharmacy - Science and Practice 26: 218-219, No. 4, Jul 2019. Available from: URL: http://doi.org/10.1136/ejhpharm-2017-001232 -Spain

Titel: Bevacizumab
Hypersensitivity reaction: case report
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-65833-8

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Bevacizumab

Hypersensitivity reaction: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Carfilzomib

Isoniazid

Chloroquine

Prasugrel/ticagrelor

Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide and Guggulsterones interaction

Cyclophosphamide